Finance

Lists
Why is VKTX up 5.95%?
Dive Deeper
VKTX:NASDAQ
Viking Therapeutics Inc
$29.22
+5.95%
(+1.64) 1D
Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VKTX...
Open
$27.44
High
$29.96
Low
$26.69
Mkt. cap
3.73B
Avg. vol.
4.70M
Volume
8.87M
52-wk high
$43.10
52-wk low
$23.82
EPS
-$5.41
Beta
0.79
Shares outstanding
127.52M
No. of employees
74
Open
$27.44
High
$29.96
Low
$26.69
Mkt. cap
3.73B
Avg. vol.
4.70M
Volume
8.87M
52-wk high
$43.10
52-wk low
$23.82
EPS
-$5.41
Beta
0.79
Shares outstanding
127.52M
No. of employees
74
News stories
From web sources and news partners
About Viking Therapeutics Inc
CEOBrian Lian
Employees74
Founded2012
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitevikingtherapeutics.com
Analyst ratings
Based on 17 analysts giving stock ratings to VKTX in the past 3 months
Strong buy
Buy
16
Hold
1
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for VKTX in the last 3 months.
Highest
Current $29.22
$125.00 (+327.79%)
Average
$95.06 (+225.33%)
Lowest
$34.00 (+16.36%)
Analyst
Recommendation
Action
Price target
Projected
Date
Naz Rahman
Maxim Group
Buy
Reiterated
$70.00
+139.6%
10/30/2026
Edward Nash
Canaccord Genuity
Buy
Maintained
$118.00
+303.8%
10/30/2026
William Wood
B. Riley Securities
Buy
Maintained
$85.00
+190.9%
10/29/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$95.00
+225.1%
10/29/2026
Jay Olson
Oppenheimer
Buy
Maintained
$120.00
+310.7%
10/29/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
$95.00
+225.1%
10/29/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
$100.00
+242.2%
10/28/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$118.00
+303.8%
10/29/2026
Joon Lee
UBS
Buy
Maintained
$94.00
+221.7%
10/29/2026
Jeet Mukherjee
BTIG
Buy
Maintained
$125.00
+327.8%
10/29/2026
Biren Amin
Piper Sandler
Buy
Reiterated
$90.00
+208%
10/29/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$102.00
+249.1%
10/29/2026
Richard Law CFA
Goldman Sachs
Hold
Reiterated
$34.00
+16.4%
10/28/2026
Unknown Analyst
UBS
Buy
Initiated
$94.00
+221.7%
10/15/2026
Gregory Renza
Truist Financial
Buy
Maintained
$85.00
+190.9%
10/07/2026
Roger Song
Jefferies
Buy
Maintained
$101.00
+245.7%
09/23/2026
Daniel Brims
Lake Street
Buy
Reiterated
$89.00
+204.6%
09/23/2026
Unknown Analyst
Goldman Sachs
Hold
Maintained
$38.00
+30%
09/22/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
09/22/2026
Hardik Parikh
J.P. Morgan
Buy
Maintained
$65.00
+122.5%
08/11/2026
Ryan Deschner
Raymond James
Buy
Maintained
-
-
06/24/2026
Unknown Analyst
B. Riley Securities
Buy
Initiated
$85.00
+190.9%
02/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
153.46M
150.15M
115.75M
166.80M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.28M
13.98M
16.84M
20.31M
Operating expense
164.74M
164.12M
132.60M
187.11M
Total operating expenses
164.74M
164.12M
132.60M
187.11M
Operating income
-164.74M
-164.12M
-132.60M
-187.11M
Other non operating income
-
-
-
-
EBT including unusual items
-157.66M
-158.32M
-128.02M
-183.19M
EBT excluding unusual items
-157.70M
-158.32M
-128.05M
-183.19M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-157.66M
-158.32M
-128.02M
-183.19M
Net profit margin
-
-
-
-
Earnings per share
-1.38
-1.37
-1.10
-1.55
Interest and investment income
7.04M
5.80M
4.54M
4.01M
Interest expense
-
-
-
-88.00K
Net interest expenses
7.04M
5.80M
4.54M
3.93M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps